Is 12 Months of Hormone Therapy Enough? Radiation & AI in Prostate Cancer with Dr. Dan Spratt

For decades, men with high-risk prostate cancer have routinely been told they need 18 to 36 months of androgen deprivation therapy (ADT) alongside radiation.But what if 12 months is enough?In this episode of the Dr. Geo Prostate Podcast, Dr. Geo Espinosa welcomes internationally recognized radiation oncologist Dr. Dan Spratt, Chair of Radiation Oncology at University Hospitals/Case Western Reserve University, to discuss groundbreaking research that could change how advanced prostate cancer is treated.Together they explore the latest MARCAP consortium data suggesting many men may receive the same cancer control with significantly less hormone therapy—potentially reducing years of unnecessary side effects while maintaining excellent outcomes. They also discuss how physicians personalize treatment decisions, the growing role of artificial intelligence with Artera AI, and why the future of prostate cancer treatment may involve doing less, not more.If you or someone you love is facing radiation therapy for prostate cancer, this episode provides one of the most important conversations happening in prostate cancer care today.What You'll Learn✔ Why 2-3 years of ADT may not be necessary for many patients✔ The new evidence supporting approximately 12 months of hormone therapy✔ Why longer hormone therapy can permanently affect testosterone recovery✔ How physicians balance cancer control with quality of life✔ The difference between NCCN guidelines and individualized patient care✔ Which patients may still benefit from longer hormone therapy✔ How AI (Artera AI) is helping personalize prostate cancer treatment✔ Why prostate cancer care is shifting toward treatment de-intensification✔ The future of precision medicine in radiation oncologyEpisode Timestamps00:00 Introduction01:30 Meet Dr Dan Spratt02:22 Why ADT Lasts Years05:42 How ADT Helps Radiation08:49 Personalizing ADT Duration12:39 Guidelines and Real World Use18:03 Who Needs Long Term ADT21:13 Artera AI Explained23:19 Old Data and Modern Outcomes27:28 De Intensification Future31:33 Biomarkers for Urologists33:57 Choosing Artera vs Decipher37:28 Final Takeaways and OutroKey Discussion PointsNew MARCAP consortium analysis on ADT durationRadiation sensitivity and androgen deprivationWhy many men never fully recover testosterone after prolonged ADTBalancing survival outcomes with quality of lifeShared decision-making between physician and patientGenomic classifiers including DecipherAI biomarkers and Artera AIPersonalized radiation oncologyModern imaging and PSMA PETDe-intensifying prostate cancer treatmentPrecision medicine in localized prostate cancerThe future of individualized prostate cancer careResources Mentioned• MARCAP Consortium research on androgen deprivation therapy duration• NCCN Prostate Cancer Guidelines (discussed throughout the episode)• Artera AI clinical decision support platform (discussion)• Decipher genomic classifier• PSMA PET imaging• MRI-guided prostate cancer staging___________________________________💪 Exclusive MembershipWant deeper insights? Join The Dr. Geo Prostate Podcast Exclusive Membership for curated transcripts, detailed show notes, expert resources, and member perks. → https://drgeo.com/membership___________________________________📌 Follow and Connect📺 YouTube → Dr. Geo Prostate Podcast — https://www.youtube.com/@DrGeoProstatePodcast🎧 All Episodes → Captivate.fm Archive — https://dr-geo-prostate-podcast.captivate.fm📸 Instagram → https://bit.ly/DRGEO-INSTA-YT📘 Facebook → https://bit.ly/POD-FB-DrGeo💼 LinkedIn → https://bit.ly/DRGEO-LINKEDIN-YT🛒 Supplements → XY Wellness<a href="https://bit.ly/3uJPC7Z?utm_source=chatgpt.com" rel